Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q1 2026 › vs Q1 2025
Ginkgo Bioworks Holdings (DNA) Q1 2026 vs Q1 2025 (year over year)
Ginkgo Bioworks Holdings's revenue fell $18.8M (-49%) from $38.2M in Q1 2025 to $19.5M in Q1 2026.
Ginkgo Bioworks Holdings, Q1 2026: revenue $19.5M (-49% year over year), operating margin -366.5%, net loss $82.6M, operating cash flow −$46.7M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $19.5M | $38.2M | −$18.8M | -49% |
| Income tax benefit | $80K | −$88K | $168K | — |
| Net loss | $82.6M | $91.0M | −$8.4M | -9% |
| Costs & expenses | $102M | $129M | −$27.0M | -21% |
| Operating costs | $90.8M | $119M | −$28.4M | -24% |
| Interest & other, net | $11.3M | $9.9M | $1.4M | +14% |
| Cost of revenue | $3.1M | $4.1M | −$992K | -24% |
| Research & development | $49.9M | $70.9M | −$21.0M | -30% |
| General & admin | $37.8M | $39.7M | −$1.9M | -5% |
| Operating cash sources | $82.6M | $91.0M | −$8.4M | -9% |
| Depreciation & amortization | $12.8M | $14.8M | −$2.0M | -14% |
| Share-based compensation | $15.9M | $17.4M | −$1.5M | -9% |
| Working capital & other | $7.2M | $7.2M | $21K | +0.3% |
| Cash used in operations | $46.7M | $51.5M | −$4.8M | -9% |
| Net loss absorbed | $82.6M | $91.0M | −$8.4M | -9% |
Questions
How much did Ginkgo Bioworks Holdings's revenue grow year over year in Q1 2026?
Ginkgo Bioworks Holdings's revenue fell $18.8M (-49%) from $38.2M in Q1 2025 to $19.5M in Q1 2026.